Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal Substance P Challenge Study
NCT04676763Phase 1Completed
- Sponsor
- GSK
- Start
- Mar 2021
- Primary completion
- Jul 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial of substance p in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and pseudoallergy (2 cohorts), sponsored by GSK. Primary endpoint: Wheal Response-time Area Under the Curve (AUC) at Week 2. Started Mar 2021; status: completed.
02
Drugs
substance p
03
Conditions
chronic spontaneous urticaria (CSU)chronic inducible urticaria (CIndU)pseudoallergy
Beyond the preview
Go deeper on NCT04676763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676763.